Edgar Filing: NOVAVAX INC - Form 4

NOVAVAX Form 4	INC						
March 17, 20	016						
					OMB A	PPROVAL	
	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						
Check thi if no long subject to Section 14 Form 4 or Form 5 obligatior may conti <i>See</i> Instru 1(b).	er 6. Filed pur inue. Section 17(STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940					
(Print or Type R	Responses)						
1. Name and Address of Reporting Person <u>*</u> Glenn Gregory M			. Issuer Name and Ticker or Trading mbol OVAVAX INC [NVAX]	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (Middle) 3. I	Date of Earliest Transaction	(Check all applicable)			
C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD			onth/Day/Year) /15/2016	Director 10% Owner X Officer (give title Other (specify below) below) President, R&D			
			lf Amendment, Date Original ed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
GAITHERS	BURG, MD 208	78		Form filed by Mo Person	ore than One Re	porting	
(City)	(State)	(Zip)	Table I - Non-Derivative Securities A	cquired, Disposed of,	or Beneficial	lly Owned	
	2. Transaction Date (Month/Day/Year)	Execution Date any	3. 4. Securities e, if TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price	SecuritiesForBeneficially(D)Owned(I)	orm: Direct)) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Repo	ort on a separate line	e for each class o	of securities beneficially owned directly o	or indirectly			
reminder, rep	ere on a separate mit		Persons who res information conta required to respo	pond to the collecti ained in this form a ond unless the form atly valid OMB cont	re not	EC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date 3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year) Execution Da	te, if Transa	ctionDerivative	Expiration Date	Underlying Securities
Security	or Exercise	any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: NOVAVAX INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A Disposed o (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	\$ 4.99	03/15/2016		А		350,000		(1)	03/15/2026	Common Stock	350,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Glenn Gregory M C/O NOVAVAX, INC. 20 FIRSTFIELD ROAD GAITHERSBURG, MD 20878			President, R&D				
Signatures							
/s/ John A. Herrmann III, Attorney-in-Fact		03/17	//2016				

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. 2015 Stock Incentive Plan vest on the first
 (1) anniversary of the March 15, 2016 grant date, and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years subject to continued employment through the vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.